Friday, February 14, 2020 11:49:28 PM
MRNA Stock Dips After Update
Moderna is testing vaccines and therapeutics that rely on messenger RNA, or mRNA. This form of RNA delivers the instructions for protein creation from the DNA.
Late Monday, Moderna said it enrolled the first patient in a Phase 1 and Phase 2 study of a drug to treat methylmalonic acidemia. In this disorder, a patient's body can't break down some fats or proteins. This results in a buildup of acid in the blood.
"This study will provide important information about the potential of an mRNA approach to replace the deficient enzyme in patients with MMA, which currently has no approved medical therapy or investigation medicine that address the underlying cause," Chief Medical Officer Tal Zaks said in a written statement.
Moderna expects to have the results of a Phase 2 study of a vaccine in the third quarter. The vaccine aims to prevent cytomegalovirus, or CMV. CMV is a common virus that doesn't cause symptoms in healthy people. But it can be a problem in people with compromised immune systems and in pregnant women.
Biotech Company Targets Coronavirus
The biotech company also announced three new vaccine efforts in Epstein-Barr virus, respiratory syncytial virus in young children and novel coronavirus.
Epstein-Barr is a type of herpes virus. Respiratory syncytial virus can cause cold-like symptoms and can be serious in infants and adults. Novel coronavirus has become well known in China for its rapid spread and a growing number of deaths beginning in December.
Investment bank Chardan kept its buy rating on MRNA stock.
"Prophylactic vaccines continue to be an area of forward momentum and we expect this will remain the case in 2020," the brokerage wrote in a report to clients.
MRNA Stock Dives On Offering
But shares of MRNA stock slipped on the offering of common stock.
Underwriters will receive a 30-day option to purchase up to an additional $75 million in shares of common MRNA stock.
Representatives of Moderna declined to comment in an email to Investor's Business Daily. The company cited a quiet period related to the secondary offering.
Follow Allison Gatlin on Twitter at @IBD_AGatlin.
Recent MRNA News
- The Gross Law Firm Notifies Moderna, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline • PR Newswire (US) • 09/16/2024 09:45:00 AM
- OpenAI Unveils Strawberry AI Model Series; Boeing Stock Falls 4% Amid Strike; HR Surges 20% on Growth Forecast • IH Market News • 09/13/2024 10:12:55 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/12/2024 10:03:14 AM
- Moderna, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - MRNA • PR Newswire (US) • 09/12/2024 09:45:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/10/2024 08:15:27 PM
- Carisma and Moderna Expand Collaboration to Develop Two In Vivo CAR-M Therapies for Autoimmune Diseases • PR Newswire (US) • 09/10/2024 11:30:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/09/2024 07:29:35 PM
- Class Action Filed Against Moderna, Inc. (MRNA) - October 8, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 09/09/2024 02:26:00 PM
- Moderna, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before October 8, 2024 to Discuss Your Rights - MRNA • PR Newswire (US) • 09/05/2024 09:45:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/04/2024 09:42:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/04/2024 08:26:08 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/03/2024 07:58:08 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/03/2024 07:42:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/30/2024 08:37:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/30/2024 08:34:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/30/2024 08:32:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/29/2024 08:45:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/29/2024 08:03:37 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/29/2024 07:52:42 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/29/2024 07:43:59 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/29/2024 07:38:25 PM
- Class Action Filed Against Moderna, Inc. (MRNA) - October 8, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 08/29/2024 09:45:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/28/2024 08:47:40 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/28/2024 08:30:04 PM
- Class Action Filed Against Moderna, Inc. (MRNA) Seeking Recovery for Investors - Contact The Gross Law Firm • PR Newswire (US) • 08/26/2024 09:45:00 AM
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM